Lens Protein-Stabilizing Compound for Reversing Presbyopia and Cataracts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia and cataracts only delay progression and lack a therapeutic solution to reverse these age-related conditions, and there is an urgent need for effective medications as the aging population increases.
Innovation Solution
A compound represented by specific chemical structures is developed to target oxidative stress and amyloid aggregation, altering lens biomechanics to stabilize protein conformation and reduce disulfide bonds, thereby treating presbyopia and cataracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medicines for treating cataracts (aldose reductase inhibitors, antioxidants, nutritional metabolism drugs, Chinese herbal remedies) are used, then the deterioration of cataracts is delayed, but the condition cannot be reversed
Solution Approach 1:
The patent changes the chemical parameters of existing cataract treatment compounds by introducing specific substituent groups (R1-R8) at defined positions on the molecular structure. This modifies the biological activity of the compounds to achieve not only delay but also reversal of cataract deterioration, transforming them from preventive to therapeutic agents.
Solution Approach 2:
The invention combines multiple functional groups and structural elements into a composite molecular structure that simultaneously provides antioxidant activity, protein aggregation inhibition, and lens biomechanics modulation. This multi-functional composite approach enables the compound to reverse cataract conditions rather than merely delaying progression.
2Adaptability or versatility
If no presbyopia treatment drug is marketed (only short-acting correction like Vuity), then the current market offers limited options, but there is urgent need for effective medications as aging population increases
Solution Approach 1:
The patent develops compounds that can be administered in advance to prevent and reverse presbyopia and cataract conditions before they severely impact vision. The compounds work by stabilizing lens proteins and preventing aggregation, providing long-term therapeutic benefit rather than temporary correction.
Solution Approach 2:
The invention creates a universal compound structure that can treat multiple age-related eye conditions (presbyopia and cataracts) through a single mechanism of action. The compound addresses both oxidative stress and protein aggregation, providing broad-spectrum therapeutic coverage for aging eye diseases.
3Reliability
If the compound stabilizes protein conformation and reduces disulfide bonds, then lens biomechanics are altered with synergistic effect, but the molecular mechanism involves complex interactions
Solution Approach 1:
The patent introduces a small molecule compound as an intermediary that mediates between oxidative stress and protein aggregation pathways. The compound acts as a bridge to simultaneously reduce disulfide bonds and stabilize protein conformation, coordinating multiple protective effects through a single molecular agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively treats presbyopia and cataracts by stabilizing protein conformation and reducing disulfide bonds, providing a synergistic effect to reverse age-related lens changes.
Implementation Method 1
The compound of the present invention improves age-related changes in lens components and the resulting presbyopia and cataract by changing the biomechanical characteristics (anti-oxidative stress and anti-amyloid insoluble protein aggregation) of the lens. On the one hand, the rheology of the lens is changed by reducing the disulfide bonds between lens molecules
Implementation Method 2
Age-related changes in lens components include changes in oxidative stress, such as an increase in the proportion of protein disulfide bonds... The compound of the present invention improves age-related changes in lens components and the resulting presbyopia and cataract by changing the biomechanical characteristics (anti-oxidative stress and anti-amyloid insoluble protein aggregation) of the lens
Implementation Method 3
The molecular mechanisms of presbyopia (old eyes) and age-related cataracts are both related to oxidative stress and amyloid-insoluble proteins... The compound of the present invention improves age-related changes in lens components and the resulting presbyopia and cataract by changing the biomechanical characteristics (anti-oxidative stress and anti-amyloid insoluble protein aggregation) of the lens
Data Source
AI summary
The present invention relates to a compound based on oxidative stress and anti-amyloid aggregation mechanism, a preparation method therefor, and a use thereof. The compound of the present invention has a structure represented by formula (I) or formula (II), can change biomechanical characteristics of a lens to ameliorate age-related lens component changes as well as presbyopia and cataract caused thereby, and therefore can treat age-related presbyopia and cataract diseases and produce a synergistic effect.